BAFISONTAMAB
UNII G86X5QQ7M5

Substance Identification & Data

This profile provides standardized clinical and technical data for Bafisontamab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) G86X5QQ7M5.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2437210-79-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

G86X5QQ7M5

CAS Registry Number

2437210-79-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

BAFISONTAMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C158085

National Cancer Institute reference terminology for clinical and research data.

INN ID

11851

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

LM-244

Identifier assigned by the United States Adopted Names Council.

Substance Type

Bafisontamab

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Bafisontamab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Bafisontamab

Common Names & Synonyms

ANTI-EGFR/ANTI-C-MET BISPECIFIC ANTIBODY EMB-01

BAFISONTAMAB [USAN]

Bafisontamab [WHO-DD]

EMB01

FIT-013A

Immunoglobulin G1, bispecific, anti-(human hepatocyte growth factor receptor c-Met) (human κ-chain) fusion protein with immunoglobulin G1 anti-(human epidermal growth factor receptor) (human γ1-chain), disulfide with immunoglobulin G1 anti-(human hepatocyte growth factor receptor c-Met) human γ1-chain N-terminal fragment and immunoglobulin G1 anti-(human epidermal growth factor receptor) human κ-chain, dimer

Immunoglobulin G1-kappa-Fab, anti-[Homo sapiens MET (MET proto-oncogene receptor tyrosine kinase, HGFR, RCCP2, DFNB97)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens and humanized monoclonal antibody, bispecific; kappa light chain and gamma1 heavy chain Homo sapiens and humanized anti-MET and anti-EGFR (V-KAPPA-CKAPPA-VH-CH1-h-CH2-CH3) (1-663) [V-KAPPA Homo sapiens anti-MET (Homo sapiens IGKV1-12*01 (96.8%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108-214) -VH humanized anti-EGFR (Homo sapiens IGHV4-61*01 (89.9%) -(IGHD) -IGHJ3*02 (100%), CDR-IMGT [10.7.11] (240-249.267-273.312-322)) (215-333) -Homo sapiens IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (430) (334-431), hinge 1-15 (432-446), CH2 (447-556), CH3 E12 (572), M14 (574) (557-661), CHS (662-663)) (334-663)], (436-214''')-disulfide with Fab G1-kappa anti-MET and anti-EGFR Homo sapiens [VH (CH1-hinge) gamma1 heavy chain (1''-220'') anti-MET (Homo sapiens IGHV1-18*01 (96.9%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.10] (26-33.51-58.97-106)) (1''-117'') -Homo sapiens IGHG1*01, G1m17 (CH1 K120 (214) (118''-215''), hinge 1-5 (216''-220'') (118''-220'')], (214''-220''')-disulfide with kappa light chain Homo sapiens anti-EGFR (1'''-214''') [V-KAPPA (Homo sapiens IGKV1-33*01 (95.8%) -IGKJ4*01 (91.7%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'''-107''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'''-214''')]; dimer (442-442'':445-445'')-bisdisulfide, produced in a Chinese hamster ovary (CHO)-K1 cell line, glycoform alfa

bafisontamab [INN]

Technical Codes

EMB-01

External Clinical & Regulatory Resources

Previous UNIIG86Q3Y6U7S

Next UNIIG87210HO7A